O
AVBP icon

OrbiMed’s ArriVent BioPharma AVBP Stock Holding History

OrbiMed’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.8M Hold
3,027,328
– – 1.38% 19
2025
Q4 		$60.9M Hold
3,027,328
– – 1.24% 24
2025
Q3 		$55.9M Hold
3,027,328
– – 1.31% 22
2025
Q2 		$65.9M Hold
3,027,328
– – 1.65% 18
2025
Q1 		$56M Hold
3,027,328
– – 1.33% 24
2024
Q4 		$80.6M Hold
3,027,328
– – 1.66% 19
2024
Q3 		$71.1M Hold
3,027,328
– – 1.29% 23
2024
Q2 		$56.2M Hold
3,027,328
– – 1.11% 29
2024
Q1 		$54.1M Buy
+3,027,328
New +$61.1M 0.99% 34

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

OrbiMed's AVBP Position: Q1 2026 in Review

OrbiMed held its ArriVent BioPharma (AVBP) position steady in Q1 2026 at 3,027,328 shares worth $69.8M. The position accounts for 1.38% of the portfolio, ranked #19.

OrbiMed first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $80.6M in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • OrbiMed held 3,027,328 shares of ArriVent BioPharma worth $69.8M as of Q1 2026.
  • OrbiMed left its ArriVent BioPharma share count unchanged in Q1 2026.
  • ArriVent BioPharma made up 1.38% of OrbiMed's portfolio in Q1 2026, its #19 holding.
  • OrbiMed first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • OrbiMed's ArriVent BioPharma position peaked at $80.6M in Q4 2024.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.